19640061-1673-4f63-956d-52b2055c9f65

CooperVision and Glaukos Reduce Cost and Drive Speed to Market with Risk-based Validation

In a rapidly evolving technology and regulation landscape, Computer System Validation (CSV) is often associated with delays, inflated costs, and inefficiencies. Draft FDA guidance on Computer Software Assurance (CSA) presents an opportunity to reshape validation and enhance medical device quality, availability, and safety.

Read CooperVision and Glaukos' insights on how risk-based validation reduces costs, speeds compliance, and speeds time to market, including:

  • Implementation and change management
  • Key factors for successful implementation
  • Achieving efficiency and cost reductions

Submit

Veeva Systems would like to contact you in the future on their products and services via phone, email, and/or post. For more details on our information practices and how to unsubscribe, please see their Privacy Policy. You can unsubscribe at any time.



You have been directed to this site by Demand Papers. For more details on our information practices, please see our Privacy Policy, and by accessing this content you agree to our Terms of Use. You can unsubscribe at any time.